30-09-03 NICE Technology Appraisal Guidance No 66 - Olanzapine and valproate semisodium in the treatment of acute mania associated with bipolar I disorder
The following NICE Guidance has been considered by NHS Quality Improvement Scotland through its revised procedure of processing of NICE Guidance
NICE Technology Appraisal Guidance No 66 - Olanzapine and valproate semisodium in the treatment of acute mania associated with bipolar I disorder
NHSScotland should note that no important differences were identified for this NICE Guidance, and NHS Quality Improvement Scotland advises that it is as valid for Scotland as for England and Wales.
NHSScotland should take account of this NICE Guidance and NHS Quality Improvement Scotland email in its planning, funding and provision of services to ensure that recommended drugs or treatments are made available to meet clinical need.
NHS Quality Improvement Scotland advice represents the evidence-based view of NHS Quality Improvement Scotland.
This advice does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer.
No other publication on the NICE Guidance will be issued by NHS Quality Improvement Scotland.
Hard copies of the NICE Guidance are available from NHS Quality Improvement Scotland (contact Tracey Smiley, tel 0141 225 6993) and all NICE Guidance and NHS Quality Improvement Scotland advice is available on this website.
NICE Processing of Technology Appraisal Guidance (PDF, 18K, 7 secs) .
NICE Processing of Technology Appraisal Guidance (Word, 209K, 65 secs) .